- Home
- ENTA vs THTX Comparison
ENTA vs THTX Comparison
Compare ENTA & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- THTX
- Stock Information
- Founded
- ENTA 1995
- THTX 1993
- Country
- ENTA United States
- THTX Canada
- Employees
- ENTA N/A
- THTX N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- THTX Health Care
- Exchange
- ENTA Nasdaq
- THTX Nasdaq
- Market Cap
- ENTA 112.4M
- THTX 118.2M
- IPO Year
- ENTA 2013
- THTX N/A
- Fundamental
- Price
- ENTA $5.93
- THTX $2.65
- Analyst Decision
- ENTA Buy
- THTX Hold
- Analyst Count
- ENTA 4
- THTX 1
- Target Price
- ENTA $17.25
- THTX N/A
- AVG Volume (30 Days)
- ENTA 119.2K
- THTX 212.4K
- Earning Date
- ENTA 05-12-2025
- THTX 07-09-2025
- Dividend Yield
- ENTA N/A
- THTX N/A
- EPS Growth
- ENTA N/A
- THTX N/A
- EPS
- ENTA N/A
- THTX N/A
- Revenue
- ENTA $64,462,999.00
- THTX $88,666,000.00
- Revenue This Year
- ENTA N/A
- THTX N/A
- Revenue Next Year
- ENTA N/A
- THTX $15.13
- P/E Ratio
- ENTA N/A
- THTX N/A
- Revenue Growth
- ENTA N/A
- THTX 13.52
- 52 Week Low
- ENTA $4.09
- THTX $1.12
- 52 Week High
- ENTA $17.24
- THTX $3.13
- Technical
- Relative Strength Index (RSI)
- ENTA 55.39
- THTX 57.42
- Support Level
- ENTA $5.55
- THTX $2.54
- Resistance Level
- ENTA $6.23
- THTX $2.68
- Average True Range (ATR)
- ENTA 0.33
- THTX 0.11
- MACD
- ENTA 0.05
- THTX -0.03
- Stochastic Oscillator
- ENTA 75.31
- THTX 85.00
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.